Molecular Pathways

Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling

Ines Barone[1,2], Lauren Brusco[2], and Suzanne A.W. Fuqua[2,3]

Abstract

Estrogens play a crucial role in regulating the growth and differentiation of breast cancers, with approximately two thirds of all breast tumors expressing the estrogen receptor alpha (ERα). Therefore, therapeutic strategies directed at inhibiting the action of ERα by using anti-estrogens such as tamoxifen, or reducing estrogens levels by using aromatase inhibitors, such as letrozole, anastrozole, or exemestane, are the standard treatments offered to women with ERα-positive cancer. However, not all patients respond to endocrine therapies (termed *de novo* resistance), and a large number of patients who do respond will eventually develop disease progression or recurrence while on therapy (acquired resistance). Recently, variant forms of the receptor have been identified owing to alternative splicing or gene mutation. This article reviews these variant receptors and their clinical relevance in resistance to endocrine therapy, by addressing their molecular cross-talk with growth factor receptors and signaling components. Understanding the complexity of receptor-mediated signaling has promise for new combined therapeutic options that focus on more efficient blockade of receptor cross-talk. *Clin Cancer Res; 16(10); 2702–8. ©2010 AACR.*

Background

Human estrogen receptors belong to a superfamily of nuclear hormone receptors that function as ligand-activated transcription factors. Two isoforms of estrogen receptor have been described: ERα and ERβ. Each is encoded by unique genes, but share a common structural and functional organization. Classical estrogen receptor (ERα or hERα-66) contains an amino-terminal region that harbors the ligand-independent activation function (AF-1), a central DNA binding domain (DBD), and a carboxy-terminal hormone binding domain (HBD), which contains the ligand-dependent activation function (AF-2; Fig. 1). Binding of hormone to ERα facilitates "classical" genomic activities of the receptor (Fig. 2), and its binding to estrogen response elements (ERE) in target genes function to either activate or repress gene expression.

Estrogen actions are also mediated by other "nonclassical" mechanisms (Fig. 2): (a) ligand-independent ERα signaling, in which gene activation occurs through second-messengers downstream of growth factor signaling pathways [such as the epidermal growth factor receptor (EGFR), the insulin-like growth factor receptor (IGFR), and the G protein coupled receptor (GPCR) pathways], which alter intracellular kinase and phosphatase activity, resulting in altered phosphorylation of ERα (1); (b) rapid, "nongenomic" effects through a membrane-associated receptor; and (c) ERE-independent signaling, in which ERα regulates genes via protein-protein interactions with other transcription factors, such as c-Fos/c-Jun B (AP-1), Sp1, and nuclear factor-κB (NF-κB; refs. 2–4). These alternative mechanisms alter downstream target protein expression instrumental in cell division, angiogenesis, and survival, leading to sustained breast cancer growth and progression.

Several laboratories have evaluated the effects of phosphorylation by second-messengers on receptor action. Among the kinases that can phosphorylate ERα are important signaling molecules such as Akt, extracellular regulated kinase (*Erk*) 1/2 mitogen-activated protein kinase (MAPK), p21-activated kinase 1 (*PAK-1*), and protein kinase A (*PKA*), resulting in diverse responses to ligands (Fig. 1; ref. 5). For example, phosphorylation of ERα serine (*S*) 167 by Akt and S118 by Erk1/2 can result in acquired resistance to the anti-estrogen tamoxifen, and ligand-independent activation of ERα (6–8). Phosphorylation of S305, which is mediated by both PKA and PAK-1 signaling, can impact estrogen hypersensitivity and tamoxifen responsiveness (9–11). These phosphorylation events are complex and interdependent. For instance, phosphorylation at ERα S305 can regulate the subsequent phosphorylation of S118 (12), and receptor acetylation (9).

Authors' Affiliations: [1]Centro Sanitario and Department of Cellular Biology, University of Calabria, Arcavacata di Rende, Cosenza, Italy; [2]Breast Center; and [3]Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas

Corresponding Author: Suzanne A.W. Fuqua, Baylor College of Medicine, Breast Center, One Baylor Plaza, BCM 600, Houston, TX. Phone: 713-798-1629; Fax: 713-798-1673; E-mail: sfuqua@bcm.edu.

©2010 American Association for Cancer Research.

American Association for *Cancer Research*

Fig. 1. A representation of the structural domains, the sites of post-translational modifications, and mutations within ERα. Growth factor signaling leads to numerous downstream phosphorylation events located within the AF-1, DBD, and hinge domains, thus affecting ERα signaling through the "nonclassical" signaling pathways. Post-translational modifications located within the HBD/AF-2 domain affect the "classical" signaling pathway of ERα. In the AF-1 domain, S118 and S167 are phosphorylated by Erk1/2 and Akt, respectively, in the hinge domain, S305 by Akt, PKA, and PAK-1. Phosphorylation of these three sites regulates both ERα's sensitivity to tamoxifen as well as ligand-independent activation of the receptor. Acetylation at residues K266/8, K299, and K302/3 by p300 also modulates ERα activation. A somatic mutation, K303R, allows ERα to be more highly phosphorylated by PKA and Akt, resulting in estrogen hypersensitivity and endocrine resistance. Methylation, occurring by Set7 interaction with ERα, causes increased receptor stability and a heightened recruitment of ERα to its target genes. In the AF-2 domain, the Y537 site is target of c-Src. The Y537N mutation eliminates this phosphorylation site, resulting in constitutive receptor activity. ERα can also be modified by alternative splicing at the DNA level, resulting in exon skipping and a truncated protein with a subsequently altered function. For example, in ERα Δ3, the third exon is alternatively spliced resulting in a truncated DBD. This isoform does not bind to DNA and is a dominant negative inhibitor to the wild-type ERα. Another truncated ERα isoform is ERα-46, which is missing the AF-1 domain and has been found to localize at the plasma membrane. It acts as a competitive inhibitor to full length ERα. A third alternatively spliced form of ERα is ERα-36, which lacks the AF-1 and AF-2 domains but has an additional 27-amino-acid sequence added at the COOH terminus. This isoform also localizes to the plasma membrane and also acts as a suppressor of full length ERα.

The region between the DBD and the LBD, known as the hinge, has long been considered to simply serve as a flexible linker to orient the other two functional domains. However, it is now thought that this region is a multifunctional domain that binds a number of coregulatory proteins and participates in the binding of estrogen receptor to DNA (9, 13, 14). The lysine residues K266, K268, K299, K302, and K303 within this domain are conserved residues that can be acetylated by the histone acetylase protein p300 (Fig. 1; refs. 14–17). Acetylation of K266 and K268 induced DNA-binding and ligand-dependent activation (14), whereas acetylation of K302 and K303 inhibited ERα activation (15). The phosphorylation status of ERα S305 coordinately regulates the acetylation of the K302/303 residues, sensitizing ERα to ligand stimulation (9). ERα K302 is also methylated by the SET7 methyltransferase (Fig. 1); this methylation stabilizes the receptor and is necessary for the efficient recruitment of ERα to its target genes and subsequent transactivation (18). Acetylation of K303 attenuates ERα-driven transcription, not just from antagonism via acetylation, but also by inhibition of K302 methylation and subsequent destabilization of

ERα. Other modifications, such as ubiquitination at K302 (19) and sumoylation at K266 and K268 (20), have also been shown to affect ERα stability and activity. Thus residues in the hinge domain are frequent targets for post-translational modifications that affect hormone sensitivity through alteration of receptor stability or regulation of estrogen-dependent gene transcription. It is tempting to speculate that immunohistochemical quantitation of these post-translational modifications could provide important prognostic or predictive information in clinical samples.

Variant ERα Protein Isoforms

Several groups have identified ERα splice variants in a number of different normal tissues such as human breast epithelium, endometrium, and pituitary, as well as various tumor types including breast cancer, endometrial carcinoma, and meningiomas; these mRNA variants are usually co-expressed along with the wild-type receptor (reviewed in ref. 21). These splice variants can confer

either dominant-positive or dominant-negative effects on cancer cells, and are hypothesized to contribute to the hormone-independent phenotype of some breast tumors. Among these variants is ERα exon Δ3, that is missing part of the DBD (22), which showed the most significant increase in levels in breast cancer tissue (Fig. 1; ref. 23). The ERα Δ3 isoform functions as a dominant-negative receptor, able to suppress estrogen-induced transcriptional activity (24), reduce anchorage-dependent growth, soft-agar colony forming ability, and *in vitro* invasion when transfected in breast cancer cells (25). It is hypothesized that this reduction in estrogen receptor signaling may lead to unchecked estrogen stimulation, establishing permissive conditions for further carcinogenetic events.

Despite the different estrogen receptor splice variants described thus far, relatively few variant ERα protein isoforms have been characterized, in part owing to the practical limitations of their detection (26–28). Previous reports have shown the presence of three predominant bands of 35 to 39, 46, and 66 kDa in immunoblots probed with an anti-ERα antibody raised against the LBD (26–28). There is accumulating evidence that these isoforms could play significant roles in estrogen receptor signaling events.

For instance, the hERα–46 isoform has been biochemically isolated from MCF-7 breast cancer cells (29), vascular endothelial cells (30), and osteoblasts (26). This isoform lacks the first 173 amino acids in the amino-terminal AF-1 domain because of alternative splicing of exon 1, and it copurifies with plasma membrane markers (Fig. 1; ref. 31). This altered location allows cells to mediate rapid estrogen signaling events, such as stimulation of nitrogen oxide synthesis (27). hERα–46 forms heterodimers with full-length ERα acting as a strong competitive inhibitor in ERα-positive cells, and it can promote activation of genomic activities in ERα-negative tissues (26, 29). Further studies are needed to identify the exact


Fig. 2. A representation of the "classical" and "nonclassical" estrogen receptor signaling pathways. Estrogen receptor mediates transcription of its target genes using two types of mechanisms, these are known as "classical" and "nonclassical" signaling. First, "classical" signaling initiates with the binding of estrogen to estrogen receptor, causing it to bind directly to regions of DNA called EREs, located within transcriptional start sites of estrogen-regulated genes, which subsequently activate transcription of downstream genes. There are several mechanisms of "nonclassical" signaling. The first of these mechanisms is mediated by the signaling of growth factors (such as IGFR and EGFR) and G-protein coupled receptors, through downstream signaling molecules to estrogen receptor. These pathways mediate estrogen receptors' state of post-transcriptional modification (by affecting its phosphorylation, acetylation, methylation) and thus its activity, independent of estrogen binding. It is likely that crosstalk of these pathways not only results in estrogen-independent activation of estrogen receptor but also endocrine resistance. Signaling has also been shown to occur through truncated membrane bound forms of estrogen receptor; this signaling is usually inhibitory of full length estrogen receptor activity. Finally, another mechanism of "nonclassical" signaling requires the binding of estrogen receptor to other transcription factors (including SP-1 and AP-1), causing a recruitment of estrogen receptor to transcriptional start sites other than EREs and transcription of downstream genes.

Table 1. Clinical trials using drugs that target pathways known to interact with the ERα pathway in patients with ERα-positive breast disease

Drug/Combination	Pathway Target(s)	Patient Disease Information	Phase	Status
PD-325901*	MEK (MAPK pathway)	Advanced breast cancer, colon cancer, and melanoma	I-II	Terminated
Bevacizumab + sorafenib tosylate[†]	RAF (MAPK pathway)	Refractory, metastatic, or unresectable solid tumors	I	Ongoing
Paclitaxel and RAD001 followed by FEC (chemotherapy)[‡ §]	mTOR	Triple negative breast tumors	II	Recruiting
Ritonavir (preoperative)[‖]	Akt	Newly diagnosed breast cancer patients	I-II	Not yet open
GSK2141795[¶]	Akt	Solid tumors/lymphomas not responsive to other therapies	I	Recruiting
GDC-0941 + bevacizumab + paclitaxel**	PI3K	Locally recurrent or metastatic breast cancer	Ib	Recruiting
BGT226[§]	PI3K	Advanced solid malignancies including breast cancer	I-II	Recruiting
BEZ235[§]	PI3K	Advanced solid malignancies including breast cancer	I	Recruiting
Temsirolimus[† ††]	mTOR	Locally recurrent or metastatic breast cancer	II	Ongoing
XL147+ XL647[‡‡]	PI3K	Solid tumors including breast cancer	I	Suspended

NOTE: Information from http://.ClinicalTrials.gov. Study sponsors footnoted below.

Abbreviation: mTOR, mammalian target of rapamycin.

*Pfizer.

[†]NCI.

[‡]MD Anderson, Houston, TX.

[§]Novartis.

[‖]Masonic Cancer Center, University of Minnesota.

[¶]GlaxoSmithKline.

**Genentech.

[††]University of Chicago.

[‡‡]Exelixis.

function of this isoform in estrogen target cell proliferation, and to understand its potential prognostic role in clinical samples.

hERα–36 is a naturally occurring isoform that is expressed in both ERα-positive and -negative breast cancer cells, and is generated from a promoter located in the first intron of the *hERα–66* gene (32, 33). It lacks both AF-1 and AF-2, but retains the DBD and portions of the HBD (Fig. 1). It possesses an extra, unique 27-amino-acid domain that replaces the last 138 amino acids encoded by exons 7 and 8 of the *hERα–66* gene (28). The hERα–36 isoform also contains three potential myristoylation sites located near the amino-terminal region, which are postulated to direct it to the plasma membrane. This isoform lacks intrinsic transcriptional activity, but it efficiently suppresses the transactivation activities mediated by full-length ERα, suggesting that it is a potent inhibitor of genomic estrogen signaling. Interestingly, the hERα–36 isoform primarily localizes to the plasma membrane, where it transduces "nongenomic" signaling cascades ini-

tiated by both estrogens and anti-estrogens, such as activation of the MAPK/ERK signaling pathway, thus stimulating cell proliferation (34). In clinical samples, overexpression of hERα-36 was associated with poorer disease-free survival in patients, identifying a subset of patients who are less likely to benefit from tamoxifen treatment (33). In summary, ERα protein isoforms capable of modulating ERα-mediated signaling have been identified, and their integration into the accurate classification of ERα status may be warranted.

ERα Mutations in Tumors

The number of naturally occurring mutations identified in breast cancers to date is relatively low (35), which is surprising because mutation of the clinical target is a common resistance mechanism in tumors. The Y537N (Tyr537Asn) mutation was discovered in a metastatic breast tumor (36). This mutation eliminates a carboxy-terminal

tyrosine residue that is considered to be an important c-Src phosphorylation site with potential roles in regulating ligand binding, homodimerization, and transactivation of ERα. It was shown that the Y537N ERα mutant exhibits constitutive transactivation activity, and that this activity was only slightly affected by estradiol, tamoxifen, or the steroidal anti-estrogen ICI 164,384 (36). A mutation at this site may allow ERα to escape phosphorylation-mediated controls, providing cells with a potential selective advantage, but unfortunately, only a few metastatic breast tumors have yet been examined for mutations at this site.

A somatic mutation at nucleotide 908 of ERα (A908G) has been identified in about a third of premalignant breast hyperplasias and one half of invasive breast tumors from untreated patients (37, 38). The A908G mutation introduces a lysine-to-arginine transition at residue 303 (termed K303R) within the hinge domain. Molecular analyses of the K303R ERα mutation have shown that the mutated arginine at the 303 position allows ERα to be more highly phosphorylated by PKA (9) and Akt kinase signaling (39), and alters the dynamic recruitment of co-activators and corepressors, such as BRCA-1 or calmodulin (40, 41).

Overexpression of the K303R ERα mutation in ERα-positive MCF-7 breast cancer cells confers estrogen hypersensitivity (37), and decreased sensitivity to tamoxifen treatment when engaged in cross-talk with growth factor receptor signaling pathway (42). Enhanced growth factor receptor cross-talk with ERα is a known mechanism of hormone resistance in breast cancer (43). Expression of the K303R ERα mutation also conferred resistance to the nonsteroidal aromatase inhibitor anastrozole in ERα-positive cells, via a dynamic interaction between the K303R ERα mutation, S305 phosphorylation, and the IGF-1R signaling pathway (39, 44). Signaling components both upstream and downstream of the IGF-1R were altered in mutant-overexpressing cells. The frequency of the mutation is still contentious (45–49), however, the sequencing method used in some of these studies might not have been sensitive enough for straight-forward detection of this specific mutation (38). The presence of the K303R ERα mutation was associated with poor outcomes in univariate analyses of tumors from untreated breast cancer patients, and its presence was correlated with older age, larger tumor size, and lymph node-positive disease, all clinical factors associated with worse outcomes (38). Collectively these data suggest that this mutation could play an important role as a predictive marker in breast cancer, and strategies to accurately measure it in clinical samples are currently underway.

Clinical-Translational Advances

Combination therapies: How do ERα variants come into play? Because a number of different signaling pathways can be simultaneously active in ERα-positive breast tumors, and a variety of estrogen receptor activities, such as receptor turnover, cellular localization, and hormone responsiveness can all be influenced by the presence of ERα variants, strategies to prevent signaling to these variants may present a unique opportunity for complete blockade of estrogen receptor. Future directions include peptide mimetics capable of blocking altered post-translational modifications on the receptor (39, 42). We speculate that the ERα hinge region may be a particularly attractive target to block the multiple post-translational modifications, including phosphorylation, acetylation, methylation, sumoylation, and ubiquitination, occurring in this important regulatory region.

Major breakthroughs in understanding the molecular dynamics of cell-signaling networks operative in tumors are rapidly being translated into the clinic, with a number of potent drugs selectively targeting the MAPK and PI3K/Akt pathways entering into clinical trials (Table 1). There is also evidence of potential cross-talk between these signaling pathways, necessitating horizontal blockade, or combined use of multiple signaling inhibitors. The complex bidirectional cross-talk that exists between growth factor receptors, these second-messenger signaling pathways, and ERα, along with the variant ERα forms suggests that simultaneous blockade will be required to bypass resistance mechanisms or restore hormone sensitivity in some breast cancer patients. The potential utility of these new therapeutics to signaling components, along with combined ERα-directed therapy is predicted to improve clinical care and reduce mortality from breast cancer.

Conclusions

A significant challenge for effective blockade of ERα signaling is the inherent cellular heterogeneity present in breast tumors. Not only can variant forms of ERα be expressed along with wild-type receptor in tumors, but ERα-positive patients can present with alterations in the growth factor receptors themselves, as well as critical signaling molecules such as PI3K and Akt (50). Accurate determination of this molecular heterogeneity is requisite for accurate and effective treatment decisions. The development of new biomarkers to detect this heterogenity is key.

References

1. Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. J Mol Med 1998;76:469–79.
2. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990;63:1267–76.
3. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 β-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 1994;269: 12940–6.
4. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443–56.
5. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006;20:3120–32.
6. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: A new model for anti-estrogen resistance. J Biol Chem 2001;276:9817–24.
7. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491–4.
8. Lee H, Jiang F, Wang Q, et al. MEKKI activation of human estrogen receptor α and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 2000;14:1882–96.
9. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA. Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Res 2004;64:9199–208.
10. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-α and promotes hyperplasia in mammary epithelium. EMBO J 2002; 21:5437–47.
11. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 2004;5: 597–605.
12. Rayala SK, Talukder AH, Balasenthil S, et al. P21-activated kinase 1 regulation of estrogen receptor-α activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006;66:1694–701.
13. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007;67: 4514–23.
14. Kim MY, Woo EM, Chong YT, Homenko DR, Kraus WL. Acetylation of estrogen receptor α by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol 2006;20:1479–93.
15. Wang C, Fu M, Angeletti RH, et al. Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 2001;276:18375–83.
16. Fu M, Wang C, Zhang X, Pestell RG. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 2004;68: 1199–208.
17. Fu M, Wang C, Zhang X, Pestell R. Nuclear receptor modifications and endocrine cell proliferation. J Steroid Biochem Mol Biol 2003; 85:133–8.
18. Subramanian K, Jia D, Kapoor-Vazirani P, et al. Regulation of estrogen receptor α by the SET7 lysine methyltransferase. Mol Cell 2008;30:336–47.
19. Berry NB, Fan M, Nephew KP. Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol 2008;22:1535–51.
20. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor α hinge region regulates its transcriptional activity. Mol Endocrinol 2005;19:2671–84.
21. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869–98.
22. Wang Y, Miksicek RJ. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 1991;5: 1707–15.
23. Poola I, Speirs V. Expression of alternatively spliced estrogen receptor α mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol 2001;78:459–69.
24. Iwase H, Omoto Y, Iwata H, Hara Y, Ando Y, Kobayashi S. Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer. Oncology 1998;55:11–6.
25. Erenburg I, Schachter B, Mira y Lopez R, Ossowski L. Loss of an estrogen receptor isoform (ER α δ 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol 1997;11: 2004–15.
26. Denger S, Reid G, Kos M, et al. ERα gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 2001;15:2064–77.
27. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 2003;100:4807–12.
28. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem Biophys Res Commun 2005;336:1023–7.
29. Flouriot G, Brand H, Denger S, et al. Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J 2000;19:4688–700.
30. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 2000;97:5930–5.
31. Marquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001;20:5420–30.
32. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY. ER-α36, a novel variant of ER-α, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008;28:479–83.
33. Shi L, Dong B, Li Z, et al. Expression of ER-{α}36, a novel variant of estrogen receptor {α}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009;27:3423–9.
34. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-{α}, hER-{α}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 2006;103:9063–8.
35. Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995;87:446–51.
36. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1244–9.
37. Fuqua SA, Wiltschke C, Zhang QX, et al. A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res 2000;60:4026–9.
38. Herynk MH, Parra I, Cui Y, et al. Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 2007;13:3235–43.
39. Barone I, Iacopetta D, Covington KR, et al. Phosphorylation of the mutant K303R estrogen receptor α at serine 305 affects aromatase inhibitor sensitivity. Oncogene 2010, Epub 2010 Jan 25.
40. Ma Y, Fan S, Hu C, et al. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-α. Mol Endocrinol 2010;24: 76–90.

41. Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA. A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions. Breast Cancer Res Treat 2009, Epub 2009 Oct 20.

42. Giordano C, Cui Y, Barone I, et al. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305. Breast Cancer Res Treat 2010;119:71–85.

43. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631–43.

44. Barone I, Cui Y, Herynk MH, et al. Expression of the K303R estrogen receptor-α breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 2009;69:4724–32.

45. Davies MP, O'Neill PA, Innes H, Sibson DR. Hypersensitive K303R oestrogen receptor-α variant not found in invasive carcinomas. Breast Cancer Res 2005;7:R113–8.

46. Tebbit CL, Bentley RC, Olson JA, Jr., Marks JR. Estrogen receptor α (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer 2004; 40:51–4.

47. Tokunaga E, Kimura Y, Maehara Y. No hypersensitive estrogen receptor-α mutation (K303R) in Japanese breast carcinomas. Breast Cancer Res Treat 2004;84:289–92.

48. Zhang Z, Yamashita H, Toyama T, et al. Estrogen receptor α mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. Breast Cancer 2003;10:70–3.

49. Conway K, Parrish E, Edmiston SN, et al. The estrogen receptor-α A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 2005;7:R871–80.

50. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15:2472–8.

Clinical Cancer Research

Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling

Ines Barone, Lauren Brusco and Suzanne A.W. Fuqua

Updated version	Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-09-1753

Cited articles	This article cites 48 articles, 19 of which you can access for free at: http://clincancerres.aacrjournals.org/content/16/10/2702.full#ref-list-1
Citing articles	This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/16/10/2702.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/16/10/2702. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.